Related Experiment Video
Updated: Jun 5, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
Advances in CAR-T cell therapy for hematologic and solid malignancies: latest updates from 2024 ESMO Congress.
Huageng Huang1, Le Yu2, Huawei Weng2
1Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, 651 Dongfeng East Road, Guangzhou, 510060, P. R. China.
Novel chimeric antigen receptor (CAR)-T cell therapies show promise for blood cancers and solid tumors. Strategies presented at the 2024 ESMO Congress aim to overcome CAR-T limitations for improved patient outcomes.
Area of Science:
- Immunotherapy
- Oncology
- Cellular Therapy
Background:
- Chimeric antigen receptor (CAR)-T cell therapy is a rapidly advancing immunotherapy with proven success in hematologic malignancies and emerging potential in solid tumors.
- Current CAR-T efficacy is limited by challenges including poor cell expansion, persistence, adverse events, target scarcity, immunosuppression, and tumor microenvironment infiltration.
Related Concept Videos
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Mesenchymal Stem Cells
Tumor Immunotherapy

